Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jun 20 04:00PM ET
7.55
Dollar change
-0.82
Percentage change
-9.80
%
Index- P/E- EPS (ttm)-17.45 Insider Own31.01% Shs Outstand5.31M Perf Week-5.98%
Market Cap46.17M Forward P/E- EPS next Y-8.91 Insider Trans0.00% Shs Float4.22M Perf Month24.59%
Income-53.26M PEG- EPS next Q-2.36 Inst Own53.75% Short Float13.10% Perf Quarter-34.46%
Sales3.27M P/S14.12 EPS this Y63.71% Inst Trans1.70% Short Ratio3.50 Perf Half Y-77.57%
Book/sh19.04 P/B0.40 EPS next Y-17.27% ROA-38.23% Short Interest0.55M Perf Year-35.91%
Cash/sh22.56 P/C0.33 EPS next 5Y23.56% ROE-60.44% 52W Range3.76 - 46.80 Perf YTD-81.05%
Dividend Est.- P/FCF- EPS past 5Y- ROIC-44.08% 52W High-83.87% Beta2.69
Dividend TTM- Quick Ratio7.56 Sales past 5Y- Gross Margin34.50% 52W Low100.80% ATR (14)0.77
Dividend Ex-Date- Current Ratio7.56 EPS Y/Y TTM- Oper. Margin-2640.70% RSI (14)56.62 Volatility9.67% 6.95%
Employees70 Debt/Eq0.07 Sales Y/Y TTM-76.29% Profit Margin-1628.75% Recom1.00 Target Price85.25
Option/ShortNo / Yes LT Debt/Eq0.04 EPS Q/Q62.14% Payout- Rel Volume0.97 Prev Close8.37
Sales Surprise-37.80% EPS Surprise29.14% Sales Q/Q-68.46% EarningsMay 06 BMO Avg Volume157.83K Price7.55
SMA2012.74% SMA5030.39% SMA200-51.50% Trades Volume152,858 Change-9.80%
Date Action Analyst Rating Change Price Target Change
Aug-19-24Initiated H.C. Wainwright Buy $75
Jan-06-23Upgrade Piper Sandler Neutral → Overweight $2 → $3
Jan-06-23Upgrade Jefferies Hold → Buy $2.50 → $3
Mar-23-22Downgrade Piper Sandler Overweight → Neutral $15 → $4
Jan-07-22Downgrade JP Morgan Overweight → Neutral $30 → $12
Jan-06-22Downgrade Jefferies Buy → Hold
Sep-09-21Initiated SVB Leerink Outperform $29
May-17-21Resumed Piper Sandler Overweight $47
Nov-10-20Initiated Piper Sandler Overweight $35
Nov-10-20Initiated JP Morgan Overweight $33
Jun-18-25 08:00AM
Jun-13-25 08:00AM
May-29-25 08:00AM
May-20-25 08:00AM
May-16-25 08:00AM
08:00AM Loading…
May-08-25 08:00AM
May-06-25 09:35AM
08:00AM
May-01-25 09:40AM
Apr-29-25 08:30AM
Apr-23-25 04:05PM
Mar-26-25 08:00AM
Mar-14-25 12:15PM
08:00AM
Mar-10-25 09:25AM
08:00AM Loading…
08:00AM
Mar-03-25 08:00AM
Feb-12-25 07:00AM
Jan-13-25 04:32PM
Dec-13-24 08:00AM
Nov-26-24 08:00AM
Nov-19-24 01:30PM
Nov-06-24 06:05PM
04:05PM
Oct-30-24 04:05PM
Oct-22-24 08:00AM
Oct-15-24 09:00AM
Oct-11-24 08:00AM
Oct-01-24 08:00AM
Sep-30-24 08:00AM
08:00AM Loading…
Sep-24-24 08:00AM
Sep-20-24 04:52AM
Sep-19-24 08:00AM
Sep-18-24 05:00PM
Sep-13-24 08:00AM
Sep-10-24 09:40AM
Aug-21-24 09:55AM
Aug-15-24 09:00AM
Aug-09-24 12:00PM
Aug-08-24 04:05PM
Aug-07-24 12:53PM
Aug-06-24 04:05PM
Jul-30-24 04:05PM
Jul-22-24 09:00AM
Jul-10-24 08:00AM
Jun-05-24 02:30AM
Jun-04-24 09:55AM
May-22-24 04:05PM
May-21-24 08:00AM
May-16-24 09:35AM
May-07-24 09:56PM
04:05PM
Apr-30-24 04:05PM
Apr-25-24 04:05PM
08:00AM
Apr-09-24 08:00AM
Apr-03-24 08:00AM
Mar-27-24 09:55AM
08:00AM
Mar-18-24 08:00AM
Mar-12-24 04:05PM
Mar-05-24 04:05PM
Feb-26-24 08:00AM
Feb-20-24 08:00AM
Feb-13-24 08:00AM
Jan-05-24 09:40AM
Dec-07-23 04:05PM
Nov-24-23 10:26AM
Nov-20-23 04:05PM
09:10AM
Nov-13-23 08:00AM
Nov-10-23 08:05AM
Nov-07-23 08:00AM
Nov-03-23 04:30PM
Nov-02-23 06:57PM
04:05PM
Oct-30-23 01:06PM
Oct-26-23 04:05PM
Oct-25-23 08:00AM
Oct-23-23 08:00AM
Oct-03-23 07:30AM
Sep-21-23 07:30AM
Aug-03-23 04:05PM
Jul-27-23 04:05PM
Jul-19-23 07:30AM
Jun-21-23 04:30PM
Jun-07-23 07:30AM
Jun-05-23 06:09AM
May-24-23 05:26PM
May-12-23 05:05PM
May-04-23 07:25PM
04:05PM
Apr-27-23 04:05PM
Apr-17-23 06:51AM
Apr-11-23 06:50PM
Mar-29-23 04:05PM
Mar-09-23 06:25PM
04:05PM
Feb-28-23 04:05PM
Feb-16-23 08:00AM
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 5, 2018 and is headquartered in South San Francisco, CA.